Real world data on Harvoni® cure rates

October 1, 2017

Prime data shows a 97% hepatitis C cure rate based on test results

Harvoni, as a cure for hepatitis C, has been on the market since 2013. But not much real-world data has focused on laboratory cure confirmation results (i.e., achieving sustained virologic response) along with a treatment persistence assessment. This study does.

What was the study about?

Hepatitis C treatment is expensive and complex. It can have severe side effects. It requires commitment from the member to start, follow and complete the therapy. This study analyzed treatment completion/cure rates, as measured by sustained virologic response (SVR) in laboratory results. The SVR is used to determine whether the treatment response — the cure — is sustained weeks after treatment is complete. 

What did we learn?

Nearly all the commercially insured members (97 percent) who completed at least eight weeks of hepatitis C treatment with Gilead’s Harvoni® (ledipasvir/sofosbuvir) were cured of the disease. The results are similar to clinical trial data, which found cure rates of 94 to 99 percent. 

Methods

For the study, Prime researchers reviewed data from 311 commercially insured individuals who received at least eight weeks of Harvoni therapy and provided a sustained virologic response (SVR) test result to the pharmacy between 12 to 24 weeks following Harvoni use. 

Results

Researchers found 301 of 311 members (97 percent) had a SVR laboratory result of 15 or less, indicating a cure. ¹


SVR rates by weeks of therapy



Conclusions

The study group also received additional care management services from Prime Therapeutics Specialty Pharmacy.1 This included 24-hour, 7-day access to experts who closely managed the coordination of pharmacy and medical benefits and helped members follow their treatment plans. This support is associated with higher levels of adherence.

What does this mean for you?

This real world data analysis found members treated for hepatitis C virus with Harvoni through the Prime Therapeutics Specialty Pharmacy had cure rates equivalent to those reported in the clinical trial data. This finding supports both Harvoni real world effectiveness and the value of using a specialty pharmacy for hepatitis C treatment. 

Plan sponsors should make sure all members taking specialty medicines have the care management services of an accredited specialty pharmacy supporting them throughout their treatment plans. 


References

  1. At the time of this research, Prime Therapeutics Specialty Pharmacy (Prime Specialty Pharmacy) was a wholly owned subsidiary of Prime Therapeutics LLC. On April 1, 2017, Prime Therapeutics Specialty Pharmacy became part of a new company formed by Prime Therapeutics LLC and Walgreen Co., headquartered in Orlando, FL. The new company, AllianceRx Walgreens Prime, has the capacity, geographic distribution and operational efficiencies to serve large health plans and national employer groups. Prime Therapeutics retains an ownership interest in AllianceRx Walgreens Prime.

Drug names are the property of their respective owners.

Real World Analysis of ledipasvir/sofosbuvir (Harvoni®) Therapy Completion Rates and Members Achieving Sustained Virologic Response (Spring 2017)

Related research

Prime analysis

October 14, 2021

Dispel the mysteries of the autoimmune drug category

We combined integrated claims with diagnosis codes and UM data to uncover indication-specific…

Prime analysis

September 14, 2021

One plan’s journey with gene therapy

Blue Cross and Blue Shield of Kansas (BCBSKS) began preparing for gene therapy…

Prime analysis

August 17, 2021

Cost management for sky-high, high-cost gene therapy

We can still put cost management levers in place to help us get…